Chris Moran1, Richard Beare1, Thanh G Phan1, David G Bruce1, Michele L Callisaya1, Velandai Srikanth2. 1. From the Stroke and Ageing Research Group (C.M., T.G.P., V.S.), Vascular Brain Ageing Division, Department of Medicine, School of Clinical Sciences, Monash University, Melbourne; Neurosciences (C.M., T.G.P., V.S.), Monash Medical Centre, Monash Health, Melbourne; Caulfield General Medical Centre (C.M.), Alfred Health, Melbourne; Developmental Imaging (R.B.), Murdoch Children's Research Institute, Melbourne; School of Medicine and Pharmacology (D.G.B.), Fremantle Hospital, University of Western Australia; and Menzies Research Institute Tasmania (M.L.C., V.S.), University of Tasmania, Hobart, Australia. 2. From the Stroke and Ageing Research Group (C.M., T.G.P., V.S.), Vascular Brain Ageing Division, Department of Medicine, School of Clinical Sciences, Monash University, Melbourne; Neurosciences (C.M., T.G.P., V.S.), Monash Medical Centre, Monash Health, Melbourne; Caulfield General Medical Centre (C.M.), Alfred Health, Melbourne; Developmental Imaging (R.B.), Murdoch Children's Research Institute, Melbourne; School of Medicine and Pharmacology (D.G.B.), Fremantle Hospital, University of Western Australia; and Menzies Research Institute Tasmania (M.L.C., V.S.), University of Tasmania, Hobart, Australia. velandai.srikanth@monash.edu.
Abstract
OBJECTIVE: Our objective was to investigate whether type 2 diabetes mellitus (T2DM) influences neurodegeneration in a manner similar to Alzheimer disease (AD), by promoting brain β-amyloid (Aβ) or tau. METHODS: We studied the cross-sectional associations of T2DM with cortical thickness, brain Aβ load, and CSF levels of Aβ and tau in a sample of people from the Alzheimer's Disease Neuroimaging Initiative with diagnoses of AD dementia, mild cognitive impairment, and normal cognition. All (n=816) received MRI, and a subsample underwent brain amyloid imaging (n=102) and CSF Aβ and tau measurements (n=415). Analyses were performed across and within cognitive diagnostic strata. RESULTS: There were 124 people with T2DM (mean age 75.5 years) and 692 without T2DM (mean age 74.1 years). After adjusting for age, sex, total intracranial volume, APO ε4 status, and cognitive diagnosis, T2DM was associated with lower bilateral frontal and parietal cortical thickness (mL) (β=-0.03, p=0.01). T2DM was not associated with 11C Pittsburgh compound B standardized uptake value ratio (AU) in any brain region or with CSF Aβ42 levels (pg/mL). T2DM was associated with greater CSF total tau (pg/mL) (β=16.06, p=0.04) and phosphorylated tau (β=5.84, p=0.02). The association between T2DM and cortical thickness was attenuated by 15% by the inclusion of phosphorylated tau. CONCLUSIONS: T2DM may promote neurodegeneration independent of AD dementia diagnosis, and its effect may be driven by tau phosphorylation. The mechanisms through which T2DM may promote tau phosphorylation deserve further study.
OBJECTIVE: Our objective was to investigate whether type 2 diabetes mellitus (T2DM) influences neurodegeneration in a manner similar to Alzheimer disease (AD), by promoting brain β-amyloid (Aβ) or tau. METHODS: We studied the cross-sectional associations of T2DM with cortical thickness, brain Aβ load, and CSF levels of Aβ and tau in a sample of people from the Alzheimer's Disease Neuroimaging Initiative with diagnoses of AD dementia, mild cognitive impairment, and normal cognition. All (n=816) received MRI, and a subsample underwent brain amyloid imaging (n=102) and CSF Aβ and tau measurements (n=415). Analyses were performed across and within cognitive diagnostic strata. RESULTS: There were 124 people with T2DM (mean age 75.5 years) and 692 without T2DM (mean age 74.1 years). After adjusting for age, sex, total intracranial volume, APO ε4 status, and cognitive diagnosis, T2DM was associated with lower bilateral frontal and parietal cortical thickness (mL) (β=-0.03, p=0.01). T2DM was not associated with 11C Pittsburgh compound B standardized uptake value ratio (AU) in any brain region or with CSF Aβ42 levels (pg/mL). T2DM was associated with greater CSF total tau (pg/mL) (β=16.06, p=0.04) and phosphorylated tau (β=5.84, p=0.02). The association between T2DM and cortical thickness was attenuated by 15% by the inclusion of phosphorylated tau. CONCLUSIONS: T2DM may promote neurodegeneration independent of AD dementia diagnosis, and its effect may be driven by tau phosphorylation. The mechanisms through which T2DM may promote tau phosphorylation deserve further study.
Authors: Peter T Nelson; Charles D Smith; Erin A Abner; Frederick A Schmitt; Stephen W Scheff; Gregory J Davis; Jeffrey N Keller; Gregory A Jicha; Daron Davis; Wang Wang-Xia; Adria Hartman; Douglas G Katz; William R Markesbery Journal: Biochim Biophys Acta Date: 2008-08-22
Authors: Manon Brundel; Martijn van den Heuvel; Jeroen de Bresser; L Jaap Kappelle; Geert Jan Biessels Journal: J Neurol Sci Date: 2010-12-15 Impact factor: 3.181
Authors: Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski Journal: Ann Neurol Date: 2009-04 Impact factor: 10.422
Authors: Shannon L Risacher; Andrew J Saykin; John D West; Li Shen; Hiram A Firpi; Brenna C McDonald Journal: Curr Alzheimer Res Date: 2009-08 Impact factor: 3.498
Authors: Madhav Thambisetty; E Jeffrey Metter; An Yang; Hillary Dolan; Christopher Marano; Alan B Zonderman; Juan C Troncoso; Yun Zhou; Dean F Wong; Luigi Ferrucci; Josephine Egan; Susan M Resnick; Richard J O'Brien Journal: JAMA Neurol Date: 2013-09-01 Impact factor: 18.302
Authors: Tom Jeerakathil; Philip A Wolf; Alexa Beiser; Joseph Massaro; Sudha Seshadri; Ralph B D'Agostino; Charles DeCarli Journal: Stroke Date: 2004-06-24 Impact factor: 7.914
Authors: Calliope Holingue; Alexandra Wennberg; Slava Berger; Vsevolod Y Polotsky; Adam P Spira Journal: Metabolism Date: 2018-02-01 Impact factor: 8.694
Authors: Diego Z Carvalho; Erik K St Louis; Bradley F Boeve; Michelle M Mielke; Scott A Przybelski; David S Knopman; Mary M Machulda; Rosebud O Roberts; Yonas E Geda; Ronald C Petersen; Clifford R Jack; Prashanthi Vemuri Journal: Sleep Med Date: 2016-11-03 Impact factor: 3.492
Authors: Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski Journal: Alzheimers Dement Date: 2017-03-22 Impact factor: 21.566
Authors: Jeremy J Pruzin; Julie A Schneider; Ana W Capuano; Sue E Leurgans; Lisa L Barnes; Rexford S Ahima; Steven E Arnold; David A Bennett; Zoe Arvanitakis Journal: Alzheimer Dis Assoc Disord Date: 2017 Jan-Mar Impact factor: 2.703
Authors: Steven E Arnold; Zoe Arvanitakis; Shannon L Macauley-Rambach; Aaron M Koenig; Hoau-Yan Wang; Rexford S Ahima; Suzanne Craft; Sam Gandy; Christoph Buettner; Luke E Stoeckel; David M Holtzman; David M Nathan Journal: Nat Rev Neurol Date: 2018-01-29 Impact factor: 42.937